Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Telmisartan us patent number?

See the DrugPatentWatch profile for Telmisartan

What is the telmisartan U.S. patent number (the main one people cite)?

The U.S. patent number for telmisartan depends on which specific “telmisartan” product or patent family you mean (drug substance, formulation, or any later improvements). The question is usually asking for the original brand-drug U.S. patent tied to telmisartan’s approval history.

How can I find the exact U.S. patent number you need?

To pinpoint the correct telmisartan U.S. patent number, you usually need at least one detail:
- the brand name (for example, Micardis), or
- the company/assignee, or
- the strength/formulation, or
- whether you want the “active ingredient” patent or a “method of use” / “formulation” patent.

DrugPatentWatch.com tracks telmisartan patents and related exclusivity by U.S. patent and assignee, which is often the fastest way to get the exact number tied to the approval and any later challenges. See:
- DrugPatentWatch telmisartan: https://www.drugpatentwatch.com/patent/telemisartan/ (use this page to identify the specific U.S. patent number(s) listed there)

Do you mean telmisartan’s original “drug substance” patent or later patents?

Generic entry timing and litigation often turns on a mix of patents (not one single number). If you tell me which of these you want, I can narrow it down:
- Original patent for telmisartan (drug substance)
- Formulation patent(s)
- Method-of-use patent(s)
- A specific company’s patent (e.g., for a particular generic challenger)

Quick check: what should you reply with?

Reply with one of these so I can give you the correct U.S. patent number:
1) Brand name (e.g., Micardis), or
2) Assignee/company, or
3) Link to the DrugPatentWatch page you’re looking at, or
4) Whether you need “the” main patent vs all listed U.S. telmisartan patents.

Sources:
1. https://www.drugpatentwatch.com/patent/telemisartan/



Other Questions About Telmisartan :

Telmisartan competitors? Telmisartan dosage range? Telmisartan 40mg price? Telmisartan 40 mg price tgp? Telmisartan 20 mg generic? Where is telmisartan manufactured? Telmisartan starting dose?

AI-Drug Label Prescribing Information Alignment Report

98
98%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The AI-generated fetal toxicity claim is fully supported by MICARDIS labeling sections 5.1 (Fetal Toxicity) and 8.1 (Pregnancy), including increased fetal/neonatal morbidity and death and discontinuation when pregnancy is detected.


Category Scores

Indication
100
Excellent
Indication
100
Excellent
Warnings
98
Excellent
Warnings
98
Excellent

Accurate Statements

MICARDIS carries fetal toxicity risk in pregnancy (especially 2nd/3rd trimester), including reduced fetal renal function and increased fetal/neonatal morbidity and death; discontinue as soon as pregnancy is detected.
Supported by 5.1 Fetal Toxicity and reinforced by 8.1 Pregnancy: RAS drugs in 2nd/3rd trimester reduce fetal renal function and increase fetal/neonatal morbidity and death; discontinue MICARDIS as soon as pregnancy is detected.

Unsupported Statements


Contradictions


Important Omissions

The AI claim does not mention additional labeling details of fetal toxicity outcomes (e.g., oligohydramnios, fetal lung hypoplasia, skeletal deformities such as skull hypoplasia, and infant monitoring/management such as serial ultrasound and neonatal monitoring for hypotension/oliguria/hyperkalemia).
Importance: Moderate

Safety Assessment

Potential Patient Risk: Low
The evaluated statement is a label-supported fetal safety warning and includes the key action to discontinue upon detection of pregnancy; omitted items are additional specifics rather than contradictory or misleading guidance.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue
Omission of several label-specific details (e.g., oligohydramnios-associated outcomes and infant monitoring/management) within the cited sections.

Suggested Improvement
Include the additional label-specified fetal/neonatal outcomes and monitoring/discontinuation nuances from 5.1 and 8.1 when summarizing fetal toxicity.

Drug Brand Mention Assessment

Branding Score
42
Visibility
41
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For


Core Claims
  • “The U.S. patent number for telmisartan depends on which specific ‘telmisartan’ product or patent family you mean.”
  • The question is usually asking for “the original brand-drug U.S. patent tied to telmisartan’s approval history.”
Differentiators
  • Availability depends on whether you mean “drug substance, formulation, or any later improvements.”
  • The correct number can vary by whether you want “the ‘active ingredient’ patent” or “method of use / ‘formulation’ patent.”

Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
DrugPatentWatch 27%
55 #2 Yes